# Aviceda Therapeutics

**Canonical:** https://apis.io/providers/aviceda-therapeutics/  
**Website:** https://www.avicedarx.com/  
**APIs profiled:** 0

Aviceda Therapeutics is a private, late-stage clinical biotechnology company based in Cambridge, Massachusetts that describes itself as the world leader in glyco-immune checkpoint therapeutics. It develops immune-mediated therapies built on a glyco-mimetic nanoparticle platform that targets the interaction between sialic acids on cell surfaces and Siglec immune receptors in order to modulate aberrant inflammation. Its lead asset, AVD-104, is an intravitreally administered sialic-acid-coated nanoparticle being evaluated in the Phase 2/3 SIGLEC trial for geographic atrophy secondary to age-related macular degeneration. Aviceda is a therapeutics developer, not a software vendor: it publishes no developer program, no public API, and no machine-readable API artifacts.

## Kin Score — 5.4 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 5.4).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Aviceda Therapeutics Domain Security** — TLSv1.3 · HSTS · DNSSEC

## Tags

Company, Biotechnology, Pharmaceuticals, Therapeutics, Ophthalmology, Clinical Trials, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/aviceda-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.